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Summary
Human herpesvirus 8 (HHV8) is an important opportunistic infection of HIV/AIDS. However,
very little is known about antibody seropositivities to HHV8 lytic and latent antigens among HIV-
infected patients in China. Therefore, a cross-sectional study was conducted to explore HHV8
serostatus among 316 HIV-infected patients in a rural area of central China. The antibody
seropositivity to HHV8 ORF65 (lytic) and LANA (latent) antigens was 12.7% and 10.4%,
respectively. Patients who were naïve to antiretroviral therapy (ART) were more likely to be
seropositive for antibodies to ORF65 (OR: 3.79; 95% CI: 1.71–8.42) and LANA (OR: 3.77; 95%
CI: 1.55–9.14) than patients receiving ART. Patients having CD4+ cell counts less than 200
cells/mm3 were more likely to be seropositive for LANA antibody (OR: 3.53; 95% CI: 1.44–8.64)
and to have lower LANA antibody titer (p = 0.007). They were also more likely to be seropositive
for ORF65 antibody (OR: 2.12; 95% CI: 0.94–4.78) and to have a lower ORF65 antibody titer (p
= 0.065), though the difference was marginally significant. No associations between other viral
coinfections studied and antibody seropositivity to either latent or lytic HHV8 antigens were
identified. Study findings suggest that antibody responses to both lytic and latent HHV8 antigens
among HIV patients in China were fairly high and were associated with immunodeficiency status
and ART.
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1. Introduction
Human herpesvirus 8 (HHV8), also known as Kaposi’s sarcoma-associated herpesvirus
(KSHV), has been linked to a number of clinical conditions, notably Kaposi’s sarcoma (KS)
(1), multicentric Castleman’s disease (MCD) (2), and primary effusion lymphoma (PEL)
(3,4). A higher incidence of HHV8 infection has been observed among HIV-infected
patients. In fact, many epidemiological studies have suggested that there were concurrent
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Public Health Safety of the Ministry of Education, Shanghai, China., nhe@shmu.edu.cn.
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epidemics of HHV8 and HIV commencing in the early 1980s (5,6). Due to HIV infection
and the development of AIDS, individuals were more susceptible to opportunistic infections,
including HHV8. Furthermore, progressive immunologic deterioration including CD4+ T-
cell depletion and CD8+ T-cell dysfunction, the hallmarks of an untreated HIV infection,
lead to impairment of immune control of HHV8 replication and therefore ultimately
carcinogenesis, and possibly KS. Fortunately, the introduction of highly active antiretroviral
therapy (HAART) in the past two decades has effectively led to a sharp decrease in the
incidence of opportunistic infections and KS in HIV-infected patients in developed countries
where such therapies were widely available (7–9).
HAART has been widely utilized throughout China since 2003 and has significantly reduced
the mortality rate among HIV-infected patients despite the obstacle of drug resistance (10–
12). As HIV-infected patients live longer via HAART, their chances for opportunistic
infections, including HHV8 infection, might be enhanced as well. Given potentially shared
transmission routes between HHV8 and other pathogens as well as the wide spectrum of
pathogenic coinfections such as hepatitis B virus (HBV), hepatitis C virus (HCV), herpes
simplex virus (HSV), and Epstein-Barr virus (EBV) among HIV-infected patients in China
(13), their impact on HHV8 antibody response among HIV-infected patients should be
ascertained.
HHV8 viral antigens are broadly categorized into two groups: lytic antigens (e.g. ORF65)
and latent antigens (e.g. latent nuclear antigen or LANA) (14). Tests for antibodies to both
lytic and latent HHV8 antigens can be used not only to identify HHV8 infection but also to
understand their interactions with the host, e.g. the association between antibodies and
HHV8 lytic and latent antigens and development of KS (15,16). Most previous studies on
the seroprevalence of HHV8 infection report seropositivity of antibodies to any of these
antigens without differentiating specific antibody responses to lytic and latent antigens. This
could hamper thorough understanding of the HHV8 epidemic and host immune responses to
HHV8 infection. As HIV-infected patients live longer when undergoing HARRT, they have
a greater likelihood of developing KS. Identification of HHV8 serostatus and cofactors for
KS development is paramount given the widespread use of HARRT.
Therefore, the current study specifically examined antibody seropositivities to lytic and
latent HHV8 antigens among a sample of previously reported patients infected with HIV
(17). Knowledge gained from this study should help to better understand host immune
responses to HHV8 infection in the context of HIV infection and viral coinfections.
2. Materials and Methods
2.1. Study sample
As previously described (17), study participants were patients confirmed to be infected with
HIV who had been registered with the National HIV/AIDS Information System and who
were participating in an ongoing HIV cohort study that was established in 2006 in the City
of Yuncheng, Shanxi Province in Central China. This site is where the HIV epidemic was
first reported in 1996 and HIV was predominantly transmitted through plasma/blood
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donation or transfusion. Free antiretroviral treatment (ART) has been available for HIV-
infected patients since 2003 in the area studied.
Venous blood was collected by trained nurses using disposable sterile needles and tubes and
then transferred to a local laboratory within 4 h of collection. Serum samples were stored at
−80°C for HHV8, HSV-1 and HSV-2, HBV, HCV, and EBV testing. Specimens were coded
by unique identification numbers and were analyzed without knowledge of the individual
identity of the study participant. This study was approved by the Institutional Review Board
of Fudan University, China. All study participants provided written informed consent.
Data on participants’ sociodemographic characteristics, HIV transmission mode, and receipt
of HAART were obtained from the National HIV/AIDS Information System using a
standard questionnaire form.
2.2. HBV, HCV, HSV-1, HSV-2, and EBV testing
HBV surface antigen (HBsAg) and anti-HCV IgG antibody were tested using an enzyme-
linked immunosorbent assay (ELISA) (Wantai Biological Pharmacy Enterprise Co., Beijing,
China). IgG antibodies to HSV-1 and HSV-2 were detected by type-specific ELISA
(HerpeSelect 1 ELISA IgG Kit and HerpeSelect 2 ELISA IgG Kit, Focus Technologies, CA,
USA). Anti-EBV nucleic antigen (EBNA) IgG antibody was tested for using ELISA
(Euroimmun, Lübeck, Germany). All tests were performed by two independent technicians
according to the manufacturers’ standard protocols. Duplicate negative, positive, and blank
controls were always used.
2.3. HHV8 testing
An immunofluorescence assay (IFA) was performed to detect the presence of lytic or latent
antigen-specific antibodies, as previously reported (18). Briefly, Spodoptera frugiperda
clone 9 cells infected with baculovirus expressing ORF65 antigen (lytic antigen) or ORF73
(latent nucleic antigen, LANA) were harvested, fixed, and spotted individually on separate
slides for further sample testing. All serum samples were then tested at 1:40 dilution. Sera
from KS patients who previously tested seropositive and healthy individuals who previously
tested seronegative served as controls. Both lytic and latent antibody titers were further
determined with IFA using serially diluted samples ranging from 1:40 to 1:10,240. Each
slide was read independently by two experienced laboratory workers. Serostatus was
categorized as antibody seropositivity for lytic antigen (ORF65), latent antigen (LANA), and
ANY and BOTH lytic and latent antigens as previously reported (19).
2.4. CD4+ and CD8 T+ cell counts and HIV RNA quantification
The absolute number of CD4+ and CD8+ T lymphocytes in peripheral blood was estimated
using a fluorescence-activated cell analyzer with monoclonal antibodies (BD FACSCount
System, BD Biosciences, San Jose, CA, USA). Plasma HIV viral loads were quantified
using the Amplicor HIV-1 RNA Monitor Test v1.5 (Roche Diagnostics Alameda, CA,
USA).
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2.5. Statistical analysis
Original questionnaires and laboratory testing results were entered and managed in
EpiData3.0, and then the database was transferred to an SPSS database for further
management and analysis. Seroprevalence of both lytic and latent antibodies was calculated.
Pearson’s Chi-squared tests were performed to evaluate differences in seroprevalence
between subgroups. Nonparametric tests (Mann-Whitney U tests) were used to assess the
difference in geometric mean titers (GMTs) of antibodies between different groups.
Concordance between the latent and lytic serology assay was assessed using the kappa
statistic. Univariate logistic regression analysis was first done and then followed by
multivariate analysis to explore associations with seropositivity for both lytic and latent
antibodies. Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated
and used to determine whether a variable was associated with antibodies against LANA,
ORF65, ANY, or BOTH. All statistical analyses were performed using SPSS software 15.0
(SPSS, Chicago, Illinois, USA) and GraphPad Prism 5.0 (GraphPad, La, Jolla, CA, USA). A
two-sided p-value of 0.05 or less was considered statistically significant.
3. Results
3.1. Sociodemographic characteristics and seroprevalence of viral coinfections
A total of 316 HIV-infected patients were included in this study. Their sociodemographic
characteristics are shown in Table 1. Of the sample, 53.8% were males and 46.2% were
females with a mean age of 42.03 years (S.D. = 10.25). About 99.1% of the participants
belonged to the Han ethnic group. Males were more likely to drink alcohol (p < 0.001) and
smoke (p < 0.001) than females. No gender differences existed for other demographic
characteristics (Table 1).
Among the participants, 23 (7.3%) were seropositive for HBsAg, 235 (74.4%) for HCV, 236
(74.4%) for HSV-1, 65 (20.6%) for HSV-2, and 292 (92.4%) for EBV. Males had a higher
prevalence of HCV infection but lower prevalence of HSV-2 infection than females (Table
1).
3.2. Prevalence and correlates of HHV8 lytic and latent antibody seropositivity
The serostatus of lytic and latent antibodies were determined separately. Antibody
seropositivity was 12.7% for lytic antigen (ORF65) and 10.4% for latent antigen (LANA).
The two serology assays showed a moderate concordance (Kappa = 0.582). Two separate
multiple logistic regression analyses were performed to explore independent correlates with
ORF65 and LANA antibody seropositivity by adjusting for gender and age group. As shown
in Table 2, both ORF65 and LANA antibody seropositivity were significantly associated
with ART and CD4+ cell counts. Participants who were ART-naïve were more likely to be
positive for ORF65 antibody (OR: 3.79; 95% CI: 1.71–8.42) and LANA antibody (OR:
3.77; 95% CI: 1.55–9.14) than those receiving ART. Patients having CD4+ cell counts less
than 200 cells/mm3 were more likely to be seropositive for LANA antibody (OR: 3.53; 95%
CI: 1.44–8.64) and to have a lower LANA antibody titer (p = 0.007). They were also more
likely to be seropositive for ORF65 antibody (OR: 2.12; 95% CI: 0.94–4.78) and to have a
lower ORF65 antibody titer (p = 0.065) although these associations were marginally
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significant. No associations between other examined viral coinfections and antibody
seropositivity to either latent or lytic HHV8 antigen were identified.
3.3. Correlates of antibody seropositivity for ANY and BOTH lytic and latent HHV8 antigens
The seropositivity of antibodies to ANY and BOTH lytic and latent HHV8 antigens was
15.8% and 7.3%, respectively. Regression analyses revealed that patients who were ART-
naïve (OR: 3.67; 95% CI: 1.75–7.69, p = 0.001) or had low CD4+ cell counts (OR: 2.71;
95% CI: 1.29–5.68, p = 0.008) were more likely to be antibody seropositive for ANY lytic
and latent HHV8 antigens (Table 3). They were also more likely to be antibody seropositive
for BOTH lytic and latent HHV8 antigens (Table 3).
3.4. Antibody titers by different characteristics
Geometric mean titers (GMT) of antibodies to lytic and latent antigens of HHV8 were
compared according to the patient’s ART status, CD4+ count, CD8+ count, and duration of
HIV infection. Patients with CD4+ T cell counts less than 200 cell/mm3 had lower antibody
titers for latent antigen (p = 0.007) and lytic antigens (p = 0.065) (Figure 1). Antibody titers
to lytic and latent antigens of HHV8 did not differ significantly with the patient’s ART
status, CD8+ count, or duration of HIV infection (Figure 1).
4. Discussion
The present study is the first to extensively examine seroprevalence and epidemiologic
characteristics of antibodies to lytic and latent HHV8 antigens among Chinese HIV-infected
patients. This study found a seroprevalence of 12.7% for antibodies to lytic antigen
(ORF65), 10.4% for antibodies to latent antigen (LANA), 15.8% for antibodies to ANY of
the two antigens, and 7.3% for antibodies to BOTH antigens. Previous studies from China
often reported only an overall seroprevalence of antibodies to ANY lytic and latent antigens
ranging from 16.3% to 43.2% (20–23), and higher than that (15.8%) in the present study.
This further suggests that HHV8 infection is unevenly distributed across populations and
geographical regions in China (24). Moreover, the present study, by showing individualized
antibody responses to the two antigens, facilitates a better understanding of host immune
responses to HHV8 infection.
Since the introduction of ART, a dramatic decline in the incidence of HIV/AIDS
opportunistic infections has been witnessed worldwide (25,26). Data have shown that ART
may also influence HHV8 infection among HIV-infected patients in a number of ways and
decrease the risk of AIDS-KS (16,27,28). In the present study, both ART and CD4+ T cell
counts were significantly correlated with HHV8 seropositivity, further suggesting the impact
of ART on host immune responses to HHV8 infection.
In this study, HIV-infected patients who received ART treatment were less likely to be
positive for both lytic (ORF65) and latent (LANA) antibodies, although the antibody titers
of patients receiving ART and not receiving ART did not differ significantly. Since LANA
is one of the few viral proteins expressed during latency and is one of the most
immunogenetic HHV8 antigens (14), detection of antibodies to LANA is primarily used as a
marker of an established persistent latent HHV8 infection. The current findings, consistent
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with results from the Swiss HIV Cohort Study (16), suggest that ART could have a positive
effect on HHV8 infection. Nevertheless, whether or not ART can alter the latency of HHV8
infection remains an important scientific question that warrants further study in the near
future.
CD4+ and CD8+ T cells play important roles in protection against intracellular pathogens
including HHV8. In the present study, HIV-infected patients with CD4+ cell counts less
than 200 cell/mm3 were consistently found to have a higher seroprevalence but a lower titer
of both lytic (ORF65) and latent (LANA) antibodies. Previous studies also found that HIV-
infected patients with CD4+ cell counts less than 200 cell/mm3 had a higher seroprevalence
of lytic (ORF65) antibody (15,19). However, they found no association between CD4+ cell
counts and seroprevalence of latent (LANA) antibody (15,19). A possible explanation for
this discrepancy is that the current study included both patients who were ART-naïve and
those receiving ART whereas the two cited studies included either only ART-naïve patients
(15) or only patients receiving ART but not both. That said, the CD8+ cell count was not
significantly correlated with antibody responses to any of the lytic and latent antigens. This
is most likely due to the fact that CD8+ T-cells are mostly involved in cellular responses but
not humeral responses.
In addition to HHV8 coinfection, HIV patients are also living with other pathogenic viral
coinfections due to shared transmission modes (13). The current study found a high
prevalence of coinfections with HBV, HCV, HSV-1, HSV-2, and EBV. However, none
were found to be significantly associated with either of the lytic and latent HHV8 antibodies.
This finding is consistent with that of a study conducted among a sample of HIV patients in
the United States (19) but is inconsistent with that of a study conducted among a sample of
Chinese patients with chronic hepatitis B (20). More intensive and extensive research is
urgently needed to address such questions.
This study had a couple of limitations. First, the capacity to make valid causal inferences
might be limited due to the nature of a cross-sectional study design. Second, none of the
study participants had KS. Therefore, the potential relationship between host antibody
responses to lytic and latent HHV8 antigens and KS risk has by no means been defined.
In conclusion, HIV patients in Central China had relatively high antibody seropositivity to
lytic and latent HHV8 antigens, and this seropositivity was significantly associated with
ART status and CD4+ cell counts. More extensive and prospective studies are urgently
needed to address controversial findings and to better understand interactions between
HHV8 and the host in the context of HIV-induced immunodeficiency being treated by or not
being treated by ART.
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Figure 1. Box-and-whisker plots of HHV8 lytic and latent antibody titer by HIV-related factors
(A) Antibody titer for patients receiving ART and not receiving ART. (B) Antibody titer for
patients with CD4 ≤ 200 cells/mm3 and CD4 > 200 cells/mm3. (C) Antibody titer for
patients with CD8 ≤ 400 cells/mm3 and CD8 > 400 cells/mm3. (D) Antibody titer for
patients infected with HIV ≤ 10 yr and those infected with HIV > 10 yr. Titers for different
groups were calculated and compared using Mann-Whitney U. “yr” stands for years.
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Table 1
Socio-demographic characteristics of study participants
Item Male (170) n (%) Female (146) n (%) Total (316) n (%)
Ethnicity (p = 0.252)
 Han 167 (98.2) 146 (100.0) 313 (99.1)
 Other 3 (1.8) 0 (0) 3 (0.9)
Age group (p = 0.530)
 0–18 5 (2.9) 6 (4.1) 11 (3.5)
 19–49 123 (72.4) 111 (76.0) 234 (74.1)
 50+ 42 (24.7) 29 (19.9) 71 (22.5)
Marital status (p = 0.346)
 Married 156 (91.8) 136 (93.2) 292 (92.4)
 Single 7 (4.1) 8 (5.5) 15 (4.7)
 Divorced/widowed 7 (4.1) 2 (1.4) 9 (2.8)
Education (p < 0.001)
 Illiterate 10 (5.9) 17 (11.6) 27 (8.5)
 Primary school 52 (30.6) 67 (45.9) 119 (37.7)
 Middle school 95 (55.9) 59 (40.4) 154 (48.7)
 High school or higher 13 (7.6) 3 (2.1) 16 (5.1)
Farmer (p = 0.409)
 Yes 154 (90.6) 136 (93.2) 290 (91.8)
 No 16 (9.4) 10 (6.8) 26 (8.2)
Monthly income (RMB, p = 0.779)
 < 1,000 97 (57.1) 82 (56.2) 179 (55.6)
 1,001–2,000 35 (20.6) 36 (24.7) 71 (22.5)
 2,001–3,000 12 (7.1) 10 (6.8) 22 (7.0)
 > 3,000 26 (15.3) 18 (12.3) 44 (13.9)
Alcohol Consumption (p < 0.001)
 Yes 26 (15.3) 3 (2.1) 29 (9.2)
 No 144 (84.7) 143 (97.9) 287 (90.8)
Smoking (p < 0.001)
 Yes 109 (64.1) 5 (3.4) 114 (36.4)
 No 61 (35.9) 141 (96.6) 202 (63.6)
HBsAg (p = 0.786)
 Positive 13 (7.6) 10 (6.8) 23 (7.3)
 Negative 157 (92.4) 136 (93.2) 293 (92.7)
HCV (p < 0.001)
 Positive 142 (83.5) 93 (63.7) 235 (74.4)
 Negative 28 (16.5) 53 (39.3) 81 (25.6)
EBV (p = 0.096)
 Positive 161 (94.7) 131 (89.7) 292 (92.4)
 Negative 9 (5.3) 15 (10.3) 24 (7.6)
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Item Male (170) n (%) Female (146) n (%) Total (316) n (%)
HSV-1 (p = 0.430)
 Positive 130 (76.5) 106 (72.6) 236 (74.7)
 Negative 40 (23.5) 40 (27.4) 80 (25.3)
HSV-2 (p = 0.012)
 Positive 26 (15.3) 39 (26.7) 65 (20.6)
 Negative 144 (84.7) 107 (73.3) 251 (79.4)
Biosci Trends. Author manuscript; available in PMC 2014 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Zhang et al. Page 12
Ta
bl
e 
2
M
ul
tiv
ar
ia
te
 a
na
ly
sis
 o
f c
or
re
la
te
s w
ith
 H
H
V
8 
ly
tic
 a
nd
 la
te
nt
 a
nt
ib
od
y 
se
ro
po
sit
iv
iti
es
 a
m
on
g 
stu
dy
 p
ar
tic
ip
an
ts
C
ha
ra
ct
er
ist
ic
s/R
isk
 fa
ct
or
LA
N
A
O
R
F6
5
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
CI
)*
p-
v
a
lu
e*
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
 C
I)*
p-
v
a
lu
e*
So
ci
o-
de
m
og
ra
ph
ic
s
 
G
en
de
r
 
 
M
al
e
11
/1
70
 (6
.5)
1.
00
18
/1
70
 (1
0.6
)
1.
00
 
 
Fe
m
al
e
22
/1
46
 (1
5.1
)
2.
53
 (1
.12
–5
.73
)
0.
02
6*
22
/1
46
 (1
5.1
)
1.
38
 (0
.67
–2
.85
)
0.
38
5
 
A
ge
 g
ro
up
 
 
0–
18
2/
11
 (1
8.2
)
1.
00
3/
11
 (2
7.3
)
1.
00
 
 
19
–4
9
24
/2
43
 (1
0.3
)
0.
36
 (0
.06
–2
.16
)
0.
26
5
30
/2
34
 (1
2.8
)
0.
33
 (0
.07
–1
.60
)
0.
17
2
 
 
50
 +
7/
71
 (9
.9)
0.
38
 (0
.05
–2
.74
)
0.
34
0
7/
71
 (9
.9)
0.
28
 (0
.05
–1
.65
)
0.
16
2
H
IV
-re
la
te
d 
fa
ct
or
s
 
A
RT
 
 
Y
es
19
/2
38
 (8
.0)
1.
00
22
/2
38
 (9
.2)
1.
00
 
 
N
o
14
/7
8 
(17
.9)
3.
77
 (1
.55
–9
.14
)
0.
00
3*
*
18
/7
8 
(23
.1)
3.
79
 (1
.71
–8
.42
)
0.
00
1*
*
 
CD
4 
(ce
ll/m
m3
)
 
 
>
 2
00
15
/1
87
 (8
.0)
1.
00
22
/1
87
 (1
1.8
)
1.
00
  ≤ 
20
0
18
/1
29
 (1
4.0
)
3.
53
 (1
.44
–8
.64
)
0.
00
6*
*
18
/1
29
 (1
4.0
)
2.
12
 (0
.94
–4
.78
)
0.
07
 
CD
8 
(ce
ll/m
m3
)
 
 
>
 4
00
27
/2
51
 (1
0.8
)
1.
00
32
/2
51
 (1
2.7
)
1.
00
  ≤ 
40
0
6/
65
 (9
.2)
0.
73
 (0
.25
–2
.14
)
0.
57
1
8/
65
 (1
2.3
)
0.
97
 (0
.37
–2
.57
)
0.
95
5
 
V
ira
l l
oa
d 
(co
pie
s/m
L)
  ≤ 
40
0
4/
25
 (1
6.0
)
1.
00
6/
25
 (2
4.0
)
1.
00
 
 
>
 4
00
29
/2
91
 (1
0.0
)
0.
47
 (0
.12
–1
.86
)
0.
28
7
34
/2
91
 (1
1.7
)
0.
42
 (0
.13
–1
.35
)
0.
14
3
 
D
ur
at
io
n 
of
 H
IV
 in
fe
ct
io
n 
(yr
)
  ≤ 
10
14
/9
7 
(14
.4)
1.
00
18
/9
7 
(18
.6)
1.
00
 
 
>
 1
0
19
/2
19
 (8
.7)
0.
59
 (0
.25
–1
.38
)
0.
22
0
22
/2
19
 (1
0.0
)
0.
54
 (0
.25
–1
.19
)
0.
12
9
Co
-in
fe
ct
io
ns
 
H
B
sA
g
 
 
N
eg
at
iv
e
29
/2
93
 (9
.9)
1.
00
35
/2
93
 (1
1.9
)
1.
00
Biosci Trends. Author manuscript; available in PMC 2014 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Zhang et al. Page 13
C
ha
ra
ct
er
ist
ic
s/R
isk
 fa
ct
or
LA
N
A
O
R
F6
5
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
CI
)*
p-
v
a
lu
e*
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
 C
I)*
p-
v
a
lu
e*
 
 
Po
sit
iv
e
4/
23
 (1
7.4
)
2.
36
 (0
.67
–8
.47
)
0.
18
2
5/
23
 (2
1.7
)
2.
41
 (0
.75
–7
.72
)
0.
14
0
 
H
CV
 
 
N
eg
at
iv
e
10
/8
1 
(12
.3)
1.
00
13
/8
1 
(16
.0)
1.
00
 
 
Po
sit
iv
e
23
/2
35
 (9
.8)
0.
52
 (0
.89
–1
.44
)
0.
21
1
27
/2
35
 (1
1.5
)
0.
63
 (0
.25
–1
.58
)
0.
32
3
 
EB
V
 
 
N
eg
at
iv
e
2/
24
 (8
.3)
1.
00
4/
24
 (1
6.7
)
1.
00
 
 
Po
sit
iv
e
31
/2
92
 (1
0.6
)
1.
88
 (0
.36
–9
.72
)
0.
45
2
36
/2
92
 (1
2.3
)
0.
93
 (0
.27
–3
.25
)
0.
90
9
 
H
SV
-1
 
 
N
eg
at
iv
e
8/
80
 (1
0.0
)
1.
00
9/
80
 (1
1.3
)
1.
00
 
 
Po
sit
iv
e
25
/2
36
 (1
0.6
)
1.
30
 (0
.52
–3
.24
)
0.
57
4
31
/2
36
 (1
3.1
)
1.
42
 (0
.60
–3
.36
)
0.
42
7
 
H
SV
-2
 
 
N
eg
at
iv
e
26
/2
51
 (1
0.4
)
1.
00
32
/2
51
 (1
2.7
)
1.
00
 
 
Po
sit
iv
e
7/
65
 (1
0.8
)
1.
03
 (0
.39
–2
.73
)
0.
95
6
8/
65
 (1
2.3
)
0.
95
 (0
.38
–2
.37
)
0.
91
7
*
Th
e 
od
ds
 ra
tio
 (O
R)
 an
d 9
5%
 C
I w
ere
 ob
tai
ne
d b
y a
dju
sti
ng
 fo
r o
the
r v
ari
ab
les
 lis
ted
 in
 th
e t
ab
le.
Biosci Trends. Author manuscript; available in PMC 2014 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Zhang et al. Page 14
Ta
bl
e 
3
M
ul
tiv
ar
ia
te
 a
na
ly
sis
 o
f c
or
re
la
te
s w
ith
 A
N
Y
 a
nd
 B
O
TH
 H
H
V
8 
ly
tic
 a
nd
 la
te
nt
 a
nt
ib
od
y 
se
ro
po
sit
iv
ity
 a
m
on
g 
stu
dy
 p
ar
tic
ip
an
ts
C
ha
ra
ct
er
ist
ic
s/R
isk
 fa
ct
or
A
N
Y
BO
TH
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
 C
I)
p-
v
a
lu
e
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
 C
I)
p-
v
a
lu
e*
So
ci
o-
de
m
og
ra
ph
ic
s
 
G
en
de
r
 
 
M
al
e
22
/1
70
 (1
2.9
)
1.
00
7/
17
0 
(4.
7)
1.
00
 
 
Fe
m
al
e
28
/1
46
 (1
9.2
)
1.
51
 (0
.78
–2
.91
)
0.
22
5
16
/1
46
 (1
1.0
)
2.
83
 (1
.05
–7
.62
)
0.
03
9*
 
A
ge
 g
ro
up
 
 
0–
18
3/
11
 (2
7.3
)
1.
00
2/
11
 (1
8.2
)
1.
00
 
 
19
–4
9
38
/2
34
 (1
6.2
)
0.
39
 (0
.08
–1
.79
)
0.
22
9
16
/2
34
 (6
.8)
0.
26
 (0
.04
–1
.69
)
0.
18
5
 
 
50
 +
9/
71
 (1
2.7
)
0.
32
 (0
.06
–1
.75
)
0.
19
1
5/
71
 (7
.0)
0.
31
 (0
.03
–2
.59
)
0.
18
1
H
IV
-re
la
te
d 
fa
ct
or
s
 
A
RT
 
 
Y
es
29
/2
38
 (1
2.2
)
1.
00
12
/2
38
 (5
.0)
1.
00
 
 
N
o
21
/7
8 
(25
.9)
3.
67
 (1
.75
–7
.69
)
0.
00
1*
*
11
/7
8 
(14
.1)
4.
36
 (1
.55
–1
2.2
7)
0.
00
5*
 
CD
4 
(ce
ll/m
m3
)
 
 
>
 2
00
25
/1
87
 (1
3.4
)
1.
00
12
/1
87
 (6
.4)
1.
00
  ≤ 
20
0
25
/1
29
 (1
9.4
)
2.
71
 (1
.29
–5
.68
)
0.
00
8*
*
11
/1
29
 (8
.5)
2.
82
 (0
.98
–8
.13
)
0.
05
4*
 
CD
8 
(ce
ll/m
m3
)
 
 
>
 4
00
40
/2
51
 (1
5.9
)
1.
00
19
/2
51
 (7
.6)
1.
00
  ≤ 
40
0
10
/6
5 
(15
.4)
0.
87
 (0
.36
–2
.08
)
0.
74
8
4/
65
 (6
.2)
0.
78
 (0
.21
–2
.91
)
0.
71
8
 
V
ira
l l
oa
d 
(co
pie
s/m
L)
  ≤ 
40
0
6/
25
 (2
4.0
)
1.
00
4/
25
 (1
6.0
)
1.
00
 
 
>
 4
00
44
/2
91
 (1
5.1
)
0.
51
 (0
.16
–1
.61
)
0.
25
2
19
/2
91
 (6
.5)
0.
31
 (0
.07
–1
.35
)
0.
12
0
 
D
ur
at
io
n 
of
 H
IV
 in
fe
ct
io
n 
(yr
)
  ≤ 
10
20
/9
7 
(20
.6)
1.
00
12
/9
7 
(12
.4)
1.
00
 
 
>
 1
0
30
/2
19
 (1
3.7
)
0.
65
 (0
.32
–1
.33
)
0.
24
0
11
/2
19
 (5
.0)
0.
41
 (0
.15
–1
.12
)
0.
07
7
Co
-in
fe
ct
io
ns
 
H
B
sA
g
 
 
N
eg
at
iv
e
44
/2
39
 (1
5.0
)
1.
00
20
/2
93
 (6
.8)
1.
00
Biosci Trends. Author manuscript; available in PMC 2014 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Zhang et al. Page 15
C
ha
ra
ct
er
ist
ic
s/R
isk
 fa
ct
or
A
N
Y
BO
TH
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
 C
I)
p-
v
a
lu
e
Po
sit
iv
es
/to
ta
l (%
)
O
R
 (9
5%
 C
I)
p-
v
a
lu
e*
 
 
Po
sit
iv
e
6/
23
 (2
6.1
)
2.
42
 (0
.82
–7
.12
)
0.
10
8
3/
23
 (1
3.0
)
2.
30
 (0
.53
–9
.98
)
0.
26
5
 
H
CV
 
 
N
eg
at
iv
e
15
/8
1 
(18
.5)
1.
00
8/
81
 (9
.9)
1.
00
 
 
Po
sit
iv
e
35
/2
35
 (1
4.9
)
0.
62
 (0
.26
–1
.42
)
0.
26
0
15
/2
35
 (6
.4)
0.
48
 (0
.14
–1
.61
)
0.
23
1
 
EB
V
 
 
N
eg
at
iv
e
4/
24
 (1
6.7
)
1.
00
2/
24
 (8
.3)
1.
00
 
 
Po
sit
iv
e
46
/2
92
 (1
5.8
)
0.
82
 (0
.24
–2
.79
)
0.
75
2
21
/2
92
 (7
.2)
0.
74
 (0
.14
–4
.11
)
0.
73
6
 
H
SV
-1
 
 
N
eg
at
iv
e
13
/8
0 
(16
.3)
1.
00
4/
80
 (5
.0)
1.
00
 
 
Po
sit
iv
e
37
/2
36
 (1
5.7
)
0.
87
 (0
.41
–1
.84
)
0.
71
6
19
/2
36
 (8
.1)
2.
23
 (0
.64
–7
.70
)
0.
20
5
 
H
SV
-2
 
 
N
eg
at
iv
e
39
/2
51
 (1
5.5
)
1.
00
19
/2
51
 (7
.6)
1.
00
 
 
Po
sit
iv
e
11
/6
5 
(16
.9)
1.
08
 (0
.48
–2
.43
)
0.
83
9
4/
65
 (6
.2)
0.
77
 (0
.25
–2
.66
)
0.
68
4
*
Th
e 
od
ds
 ra
tio
 (O
R)
 an
d 9
5%
 C
I w
ere
 ob
tai
ne
d b
y a
dju
sti
ng
 fo
r o
the
r v
ari
ab
les
 lis
ted
 in
 th
e t
ab
le.
Biosci Trends. Author manuscript; available in PMC 2014 May 11.
